

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和鉑醫藥控股有限公司
HBM Holdings Limited
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR,
CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company in relation to the increase in shareholding in the Company by Dr. Jingsong Wang (“**Dr. Wang**”), an executive director, the chief executive officer and the chairman of the board of directors of the Company (the “**Board**”).

The Board was informed by Dr. Wang that he has purchased a total of 400,000 ordinary shares of the Company (the “**Share(s)**”) in the open market on 27 January 2025, at an average price of approximately HK\$3.5 per Share, representing approximately 0.052% of the total issued Shares of the Company. Immediately after the purchase, Dr. Wang is interested in an aggregate of 70,297,400 Shares, representing 9.212% of the total issued share capital of the Company as at the date of this announcement.

As advised by Dr. Wang, he is fully confident about the overall development prospects and potential growth of the Group. Subject to compliance with applicable laws and regulatory requirements, Dr. Wang does not rule out that he may further increase his shareholding in the Company as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 28 January 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.